Send us a text Compounding Pharmacies – are you prepared for increased scrutiny? With select grace periods now behind us, FDA's focus has shifted to active enforcement. Inspections and warning letters are becoming more frequent as FDA hones in on compliance with both agency registration requirements and USP compounding standards. Today's Quality Grind Short will help you strengthen your operations, stay inspection-ready, and protect both your patients and your business. At Medvacon, our exper...

Andres Leschziner presents his paper "Structure of LRRK1 and mechanisms of autoinhibition and activation". Reimer, J. M. et al., Nat. Struct. Mol. Biol. 30, 1735–1745 (2023).

In today’s Pharmaceutical Executive Daily, we explore why medical AI success depends on more than algorithms, Amgen’s launch of its new direct-to-consumer platform AmgenNow, and AstraZeneca’s multi-target research partnership with Algen.

In today’s Pharmaceutical Executive Daily, we cover the FDA lifting its clinical hold on Neurizon Therapeutics’ lead program Nuz-001, the agency’s export ban on Sun Pharma’s Halol facility, and new insights on how small biotechs can better navigate regulatory and market complexities.

I just wanted to record a personal "thank you" to all of you for supporting my channels - all 4 of them🙏 I know there is a plethora of podcasts out there for you to choose from, so thank you all SO MUCH for choosing to listen to mine - it is very much appreciated🙏 If you have any suggestions or requests for any specific topics you'd like me to cover, please don't hesitate to ask - this is your channel as much as it is mine!

Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.In today’s Pharmaceutical Executive Daily, we cover lessons from FDA complete response letters shaping CMC strategy in cell and gene therapy, Takeda’s decision to discontinue its cell therapy research programs, and the CDC’s latest update to COVID-19 vaccination recommendations.

Episode 1: Welcome & Where We’re Headed Hosted by Vanessa Dias & Katie Boychuck In this trailer episode, we introduce the hosts and The MED13L Foundation—how it started, what drives us, and why this podcast exists. Whether you're navigating a new diagnosis, supporting a loved one, or working in research or medicine, this episode offers a personal and accessible introduction to MED13L Syndrome and the global community coming together around it. We share the story of how the Foundation...

This week’s tHEORetically Speaking News Roundup covers Pfizer’s new Medicaid pricing deal with the current administration, Cartography Biosciences’ $67M raise to advance its next-generation colorectal cancer therapy, and calls for a U.K. anticompetition probe into pharma investment freezes. Tune in for this concise recap of the key HEOR, RWE, and Market Access headlines shaping our industry.

In this video, Darshan discusses recent enforcement trends show three weak spots to watch: Encounter Quality – If prescribers are just checking boxes without real patient relationships, it’s not care—it’s exposure. Demand documented standards, ID proofing, intake, decision support, and supervision. Don’t take claims at face value—audit them. Cash Flow Logic – Murky subscription fees, misuse of facility fees, or volume-driven compensation are red flags. Require transparent fee schedules, fair...

In this episode of STBYM’s The Monstrefact, Robert discusses Lady Deathstrike from Marvel Comics…See omnystudio.com/listener for privacy information.

In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.

Global health is facing a critical moment. New scientific breakthroughs are making a huge difference in the fight against epidemics like HIV/AIDS, tuberculosis, and malaria. But funding is down and priorities are shifting. Will these diseases finally be eliminated? Or will they surge instead?On The Threshold, reporters from around the world cover this unfolding crisis from all sides—talking to scientists, politicians, civil society leaders, pharmaceutical executives, and others. The Threshold is a